Limitations
treatment-resistant
REMISSION
There are several limitations of our study. We only included male Chinese Han patients, and the response and remission rate in our study is relatively higher than in previous studies. Caution is needed in generalizing the findings to other populations, especially the treatment-resistant population. Moreover, to choose medications based on the pharmacogenomics report, clinicians were not masked to the study groups, which might increase the clinicians’ attention toward the patient’s medical treatment. Our study was a short-term study, and we did not evaluate the cost-effectiveness of pharmacogenomic testing. Long-term benefits and cost-effectiveness should be investigated in future studies with larger sample sizes and completer assessments.Evidence regarding the impact of CYP1A2 on the metabolism of antipsychotics is limited and inconsistent. As a result, we only considered its potential influence on clozapine and reduced its weight value. Nevertheless, due to the small number of patients using clozapine in our study, further research is needed to elucidate this matter more comprehensively. Moreover, while we restricted the use of CYP2D6 inhibitors, we did not limit the use of medications that might affect CYP1A2 and CYP3A4 enzymes. Factors such as smoking and coffee consumption, which can affect the activity of the CYP1A2 enzyme, were not accounted for in our study. Additionally, we did not document each nonpsychiatric medication that patients were concurrently taking. These factors must be considered in clinical practice when considering medication selection.It is important to acknowledge that our pharmacogenomic testing panel was primarily based on East Asian populations and did not encompass all potential loci and variants. For instance, our detection of 